Completed PHASE2 INTERVENTIONAL NCT00005804

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen

Sponsor: Fred Hutchinson Cancer Center

Conditions Chronic Myeloproliferative Disorders Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Precancerous/Nonmalignant Condition Small Intestine Cancer

Interventions allogeneic bone marrow transplantation cyclophosphamide radiation therapy

Updated 6 times since 2017 Last updated: Mar 31, 2010 Started: Oct 31, 1999 Primary completion: Aug 31, 2002 Completion: Aug 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00005804, this PHASE2 trial focuses on Chronic Myeloproliferative Disorders and Leukemia and remains completed. Sponsored by Fred Hutchinson Cancer Center, it has been updated 6 times since 1999, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
May 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — May 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Data source: Fred Hutchinson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seattle, United States